| 摘要: |
| [摘要]目的：研究双歧杆菌三联活菌胶囊联合山白消食合剂治疗消化不良性腹泻的临床疗效及可能机制。方法：选取2017年1月至2019年6月在徐州市儿童医院门诊治疗的140例消化不良性腹泻患儿为研究对象，按随机数字表分为对照组和试验组各70例。对照组给予消食合剂治疗，试验组在对照组的基础上联合服用双歧杆菌三联活菌胶囊，连续服用14 d，比较两组患儿主要临床症状消失时间、临床疗效、不良反应及治疗前后血清炎性因子水平、糖萼相关指标水平。结果：试验组退热时间、腹痛腹泻消失时间、呕吐消失时间均较对照组短（P<0.05）；对照组的总有效率为78.57%，试验组的总有效率为97.14%（P<0.05）；对照组总不良反应发生率为5.71%，试验组为10.00%（P>0.05）；治疗后两组血清炎性因子肿瘤坏死因子（TNF）-α、白细胞介素（IL）-6、IL-17水平均较治疗前下降，治疗后实验组血清炎性因子TNF-α、IL-6、IL-17水平均较对照组显著下降（P<0.05）；治疗后两组血清硫酸乙酰肝素、Syndecan-1、透明质酸水平均较治疗前下降，治疗组血清Syndecan-1、透明质酸水平均较对照组下降更明显（P<0.05）。结论：双歧杆菌三联活菌胶囊联合山白消食合剂治疗消化不良性腹泻的临床疗效显著，可通过抑制内皮糖萼脱落降解和降低血清炎性因子水平来改善消化不良性腹泻，促进患儿临床症状的改善。 |
| 关键词: 双歧杆菌三联活菌胶囊 山白消食合剂 消化不良性腹泻 内皮糖萼 |
| DOI：doi:10.13407/j.cnki.jpp.1672-108X.2022.05.010 |
|
| 基金项目: |
|
| Clinical Efficacy and Mechanism of Bifidobacterium Triple Live Bacteria Capsules Combined with Shanbai Xiaoshi Mixture in the Treatment of Dyspeptic Diarrhea Based on Glycocalyx Degradation |
| Sun Beibei, Wang Guangmeng, Yu Xiaohong, Zhou Qi, Feng Dongjin |
| (Xuzhou Children’s Hospital Affiliated to Xuzhou Medical University, Jiangsu Xuzhou 221000, China) |
| Abstract: |
| [Abstract] Objective: To study the clinical efficacy and possible mechanism of bifidobacterium triple live bacteria capsules combined with Shanbai Xiaoshi mixture in the treatment of dyspeptic diarrhea. Methods: A total of 140 children with dyspeptic diarrhea in the pediatric outpatients of Xuzhou Children’s Hospital from Jan. 2017 to Jun. 2019 were extracted to be divided into the control group and the experimental group via the random number table, with 70 cases in each group. The control group was treated with with Shanbai Xiaoshi mixture, while the experimental group received bifidobacterium triple live bacteria capsules on the basis of the control group. Both groups were treated for 14 d. The disappearance time of major clinical symptoms, clinical efficacy, adverse drug reactions, serum inflammatory factors before and after treatment, and glycocalyx-related indicators of two groups were compared. Results: The antipyretic time, disappearance time of abdominal pain and diarrhea, and disappearance time of vomiting in the experimental group were shorter than those in the control group (P<0.05). The total effective rate was 78.57% in the control group and 97.14% in the experimental group (P<0.05); the incidence of adverse drug reactions was 5.71% in the control group and 10.00% in the experimental group (P>0.05). After treatment, the levels of tumor necrosis factor (TNF)-α, interleukin (IL)-6 and IL-17 in two groups decreased compared with those before treatment, the levels of TNF-α, IL-6 and IL-17 in the experimental group were significantly lower than those in the control group (P<0.05). After treatment, the levels of serum heparan sulfate, Syndecan-1 and hyaluronic acid in two groups were lower than those before treatment, the levels of serum Syndecan-1 and hyaluronic acid in the experimental group were significantly lower than those in the control group (P<0.01). Conclusion: The clinical efficacy of bifidobacterium triple live bacteria capsules combined with Shanbai Xiaoshi mixture in the treatment of dyspeptic diarrhea is significant, which can improve the dyspeptic diarrhea and promote the improvement of clinical symptoms by inhibiting the shedding and degradation of endothelial glycocalyx and reducing the level of serum inflammatory factors. |
| Key words: bifidobacterium triple live bacteria capsules Shanbai Xiaoshi mixture dyspeptic diarrhea endothelial glycocalyx |
